IA
CTXR icon

Inspire Advisors’s Citius Pharmaceuticals CTXR Stock Holding History

Inspire Advisors’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-6,318
Closed -$79.1K – 431
2024
Q3 		$79.1K Sell
6,318
-12
-0.2% -$202 0.01% 416
2024
Q2 		$92.4K Buy
6,330
+33
+0.5% +$591 0.01% 368
2024
Q1 		$141K Sell
6,297
-1,013
-14% -$18.5K 0.02% 360
2023
Q4 		$138K Sell
7,310
-146
-2% -$2.77K 0.02% 325
2023
Q3 		$128K Sell
7,456
-483
-6% -$11.5K 0.02% 257
2023
Q2 		$238K Sell
7,939
-6
-0.1% -$197 0.05% 201
2023
Q1 		$232K Buy
7,945
+107
+1% +$3.08K 0.05% 171
2022
Q4 		$155K Sell
7,838
-98
-1% -$2.67K 0.04% 164
2022
Q3 		$240K Buy
7,936
+61
+0.8% +$1.68K 0.07% 91
2022
Q2 		$181K Buy
7,875
+126
+2% +$3.46K 0.05% 94
2022
Q1 		$347K Buy
7,749
+197
+3% +$7.78K 0.1% 51
2021
Q4 		$291K Buy
7,552
+2,023
+37% +$91.8K 0.08% 67
2021
Q3 		$281K Buy
5,529
+109
+2% +$5.47K 0.09% 47
2021
Q2 		$472K Buy
5,420
+989
+22% +$59.4K 0.15% 32
2021
Q1 		$197K Buy
+4,431
New +$176K 0.07% 65

Other funds holding CTXR

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return

Inspire Advisors's CTXR Position: Q4 2024 in Review

Inspire Advisors sold out of Citius Pharmaceuticals (CTXR) in Q4 2024, closing a stake of 6,318 shares — an estimated $79.1K sold.

Inspire Advisors first reported a position in CTXR in Q1 2021 and held it in 15 quarters. The position peaked at $472K in Q2 2021. 30 funds tracked by Wall St. Rank hold CTXR as of Q4 2024.

  • Inspire Advisors reported no remaining Citius Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Inspire Advisors sold 6,318 Citius Pharmaceuticals shares in Q4 2024, an estimated $79.1K.
  • Inspire Advisors first reported a position in Citius Pharmaceuticals in Q1 2021 and held it in 15 quarters.
  • Inspire Advisors's Citius Pharmaceuticals position peaked at $472K in Q2 2021.
  • 30 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q4 2024.

Based on Inspire Advisors's 13F filing for Q4 2024, filed 7 Feb 2025.